STATICH.

Trial name or title	Study of Antithrombotic Treatment after Intracerebral Haemorrhage (STATICH)
Methods	Allocation: randomised Blinding: open, blinded endpoint Duration: 2 years Design : parallel Setting: multicenter in Norway, Denmark, and Sweden Dates: start up 2017
Participants	Inclusion criteria: Spontaneous, primary ICH No preceding traumatic injury, no structural secondary underlying structural cause Indication for antithrombotic drug Uncertainty about whether to start or avoid antithrombotic drugs after ICH Patient age ≥ 18 years Patient is at least 24 hours after symptom onset Consent from patient or representative Exclusion criteria: Absolute indication for anticoagulant treatment Patient is pregnant, breastfeeding or of childbearing age and not taking contraception Patient is being treated or followed up in another CTIMP For MRI substudy: contraindication for MRI
Interventions	Interventions for each group: the intervention is starting antithrombotic drug. The comparator is avoiding antithrombotic drugs
Outcomes	Primary outcome measure: recurrent symptomatic ICH Secondary outcome measures: complication of qualifying ICH; symptomatic extradural haemorrhage, subdural haemorrhage, subarachnoid haemorrhage; symptomatic major extracranial haemorrhage; symptomatic ischaemic events; cardiovascular death; death from any other cause; mRS
Starting date
Contact information	Trial co‐ordinating investigator: Eivind Berge, MD, PhD, email: eivind.berge@medisin.uio.no Trial manager: Elisabeth Forfang, MD, email: elisabeth.forfang@medisin.uio.no
Notes

AF: atrial fibrillation
 CCA: common carotid artery
 CT: computed tomography
 DBP: diastolic blood pressure
 DOAC: direct oral anticoagulant
 ICH: intracerebral haemorrhage
 MRI: magnetic resonance imaging
 mRS: modified Rankin Scale
 NOAC: novel oral anticoagulant
 OAC: oral anticoagulation
 SBP: systolic blood pressure
 TIA: transient ischaemic stroke
 VKA: vitamin K antagonist